



Leverages team's significant scientific and financial prowess, sourcing investments in breakthrough health and life science companies

## Reasons to Invest

- ▶ Unconstrained Biotech/Healthcare Portfolio designed to outperform broad market exposure by focusing on:
  - ▶ Disruptive life sciences innovators
  - ▶ Robust cash flow/revenue growth companies
  - ▶ Direct funding through private placements, IPOs & other structured transactions
- ▶ Portfolio Manager is co-inventor of an FDA-approved therapeutic & eight drug patents
- ▶ Concentrated exposure not found in the S&P 500


## Fund Objective

The Fund's objective is to achieve long-term capital appreciation.

## Key Differentiators

- ▶ Utilizes research performed by Portfolio Manager, Mark Charest, PhD, of sub-advisor LifeSci Fund Management, and the scientists, researchers, and medical doctors at the LifeSci Partners group
- ▶ Invests in small, mid, and large cap biotech, pharmaceutical, healthcare and life science companies addressing areas of high, unmet, medical need
- ▶ Dr. Charest believes that knowing what to own is only half the battle — the real potential for victory may also lie in knowing what to avoid; that's his key to downside defense

## Growth of \$10,000 (11/29/19 to 3/31/24)



## Fund Performance as of 3/31/24 (Annualized if greater than 1 year)

Fund Inception: 11/29/19	QTD	6 Mos	YTD	1 YR	2 YR	3 YR	Inception
LYFIX	-0.77	2.69	-0.77	-0.56	1.31	0.04	11.39
LYFAX	-0.78	2.63	-0.78	-0.79	1.09	-0.21	11.16
LYFCX	-0.95	2.27	-0.95	-1.50	0.36	-0.96	10.53
S&P 500 Total Return Index	10.56	23.48	10.56	29.88	9.47	11.49	14.44
S&P Biotechnology Select Industry Total Return Index	6.47	30.09	6.47	25.67	2.99	-11.00	0.56
<b>LYFAX After Sales Charges</b>	<b>-6.47</b>	<b>-3.29</b>	<b>-6.47</b>	<b>-6.47</b>	<b>-1.88</b>	<b>-2.16</b>	<b>9.65</b>

The performance data quoted represents past performance, past performance does not guarantee future results, the investment return and principal value of an investment will fluctuate so that when redeemed, it may be worth more or less than their original cost, and current performance may be lower or higher than the performance data quoted. To obtain performance data current to the most recent month-end, please call 844-ACFUNDS (844-223-8637) or visit [www.AlphaCentricFunds.com](http://www.AlphaCentricFunds.com).

The maximum sales charge for Class "A" Shares is 5.75%. The Fund's total operating expenses are 2.00%, 2.75%, and 1.75% for the Class A, C, and I Shares respectively.

## Fund Management

**Investment Advisor**  
AlphaCentric Advisors, LLC

**Investment Sub-Advisor**  
LifeSci Fund Management

**Portfolio Manager**  
Mark Charest, PhD

▶ 14+ years as an investor at several specialized \$1B+ AUM healthcare funds

▶ Led Medicinal Chemistry Lab at the Novartis Institutes for BioMedical Research focused on Oncology drug discovery

▶ Inventor on 8 drug patents

▶ Portfolio Manager at New Leaf Venture Partners

▶ National Science Foundation Graduate Research Fellow

▶ PhD and MS in Chemistry and Chemical Biology from Harvard University

### Year-Over-Year Performance

	2023	2022	2021	2020
<b>LYFIX</b>	<b>7.17</b>	<b>-0.82</b>	<b>-3.35</b>	<b>54.78</b>
S&P Biotech Select Industry	7.76	-25.62	-20.38	48.10

### Performance & Risk Statistics (since Fund inception)

	LYFIX	S&P Biotech Select Industry
Cumulative Return	59.67%	2.45%
Annualized Return	11.39%	0.56%
Standard Deviation	22.10%	29.10%
Sharpe Ratio (RF 0.5%)	0.42	-0.05
Alpha	10.94%	-
Beta	0.60	-
R-Squared	0.62	-

### Top Ten Holdings

Holding	
Cash & Cash Equivalents	11.42%
Pfizer Inc	5.02%
Harmony Biosciences Holdings I	4.23%
United Therapeutics Corp	3.80%
Pacira BioSciences Inc	3.55%
BioCryst Pharmaceuticals Inc	3.54%
Galapagos NV	3.49%
Argenx SE	3.25%
Inari Medical Inc	3.12%
DocGo Inc	2.71%

**Number of Holdings** 62

Portfolio holdings are subject to change and should not be considered investment advice.

- ▶ The sub-advisor is an affiliate of the **LifeSci Partners** group of companies, a global provider of client services to key stakeholders in the life sciences, medical technology, and healthcare ecosystem, established in 2009.
- ▶ The LifeSci Partners team is **engaged with healthcare companies worldwide**. Dr. Charest leverages this formidable level of resources in his management of the Fund's Portfolio.

### How to Invest

Share Class	CUSIP	Net Expense	Gross Expense	
Class A LYFAX	62827P352	1.65%	2.00%	The advisor has contractually agreed to waive fees and/or reimburse expenses to maintain the Fund's total annual operating expense ratio at 1.65%, 2.40% and 1.40% for Class A shares, Class C shares and Class I shares, respectively, excluding 12b-1 fees through July 31, 2024.
Class C LYFCX	62827P345	2.40%	2.75%	
Class I LYFIX	62827P337	1.40%	1.75%	
Minimum Initial Investment: \$2,500				<b>Investors should carefully consider the investment objectives, risks, charges and expenses of the AlphaCentric Funds. This and other important information about the Fund is contained in the prospectus, which can be obtained by calling 844-ACFUNDS (844-223-8637) or at <a href="http://www.AlphaCentricFunds.com">www.AlphaCentricFunds.com</a>. The prospectus should be read carefully before investing.</b>
Minimum Subsequent Investment: \$100				

**S&P Biotechnology Select Industry Total Return Index** represents the bio-technology sub-industry portion of the S&P Total Markets. **S&P 500 Index** is considered to be generally representative of the U.S. large capitalization stock market as a whole. There is no assurance that the Fund will achieve its investment objective. You cannot invest directly in an index and unmanaged index returns do not reflect any fees, expenses or sales charges. **Alpha** is a measure of the difference between a fund's actual returns and its expected performance, given its level of risk as measured by beta. **Beta** is a measure of a fund's sensitivity to market movements. **R-Squared** is a measure of the relationship between a portfolio and its benchmark. **Sharpe Ratio** is a risk-adjusted measure of a fund's performance that indicates a fund's return per unit of risk, defining risk as volatility. **Standard Deviation** is a statistical measure of portfolio risk used to measure variability of total return around an average, over a specified period of time.

### Important Risk Information

The Fund may be susceptible to an increased risk of loss, including losses due to adverse occurrences affecting the Fund more than the market as a whole because the Fund's investments are concentrated in the biotech, pharmaceutical, healthcare facilities and other life science services. Companies in the healthcare sector, including drug and biotech-related companies, may be heavily dependent on clinical trials with uncertain outcomes and decisions made by the governments and regulatory authorities. Please see the prospectus for all of the principal risks of investing in the Fund.

Mutual Fund Investing involves additional risk, principal loss is possible. Investment in the Fund(s) is subject to investment risks, including, without limitation, concentration risk, equity risk, market risk, management risk, small company risk, mid cap stock risk, large redemption risk. Funds that invest in small and mid cap stocks are often more volatile than large cap stocks. Smaller companies generally face higher risks due to their limited product lines, markets and financial resources.

For more information about the Funds, including their objectives, charges, expenses and risks (including more information about the risks listed above), please read the funds' prospectus. Distributed by Northern Lights Distributors, LLC. (Member FINRA).

The AlphaCentric Funds are distributed by Northern Lights Distributors, LLC, member FINRA/SIPC. AlphaCentric Advisors, LLC, LifeSci Fund Management, and LifeSci Partners are not affiliated with Northern Lights Distributors, LLC. | ©2024 AlphaCentric Advisors | 8039-NLD-04/09/2024